NCT03326336 - Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

October 26, 2027

Study Completion Date

October 26, 2027

Conditions

Non-syndromic Retinitis Pigmentosa

Interventions

COMBINATION_PRODUCT

Gene therapy: GS030-DP AND Medical device: GS030-MD

GS030-Drug Product (GS030-DP) - Recombinant adeno-associated viral vector, derived from serotype 2 (rAAV2.7m8), containing the optimized channelrhodopsin ChrimsonR-tdTomato gene under the control of the ubiquitous CAG promoter (rAAV2.7m8-CAG-ChrimsonR-tdTomato) GS030-Medical Device (GS030-MD) - Visual Interface Stimulating Glasses (that amplify the external visual stimulus to the optogenetically engineered retina)

Trial Locations (3)

15213

UPMC Eye Center, Pittsburgh

75012

Centre Hospitalier National d'Ophtalmologie (CHNP) des Quinze-Vingts, Paris

Unknown

Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London